On the public citation graph
The Pan-PPAR Agonist Lanifibranor Reverses Metabolic Dysfunction in People with Type 2 Diabetes and MASLD: A Randomised, Double-Blind, Placebo-Controlled, Phase 2 Trial
0 signed · 35 inferred · view as graph
Inferred edges come from two machine sources: sweeps of open repository metadata (mostly SSRN and Zenodo), and a bulk OpenAlex citation snapshot. Every row below is labelled with the one it came from. Neither is a complete citation index — absence here is not evidence of absence.
Is this your work? Sign in with ORCID and put your name on the
claims that are yours.
Reference health. See whether every reference in this work resolves to a
known work and none has been retracted — and get a dated CiteStamped
badge you can embed.
What this work says
Outgoing claims: the papers this work cites, builds on, or argues with.
inferredcites →https://doi.org/10.1002/hep.25539openalex-extracted
Effect of adipose tissue insulin resistance on metabolic parameters and liver histology in obese patients with nonalcoholic fatty liver disease
inferredcites →https://doi.org/10.1002/hep.28985openalex-extracted
Metabolic and histological implications of intrahepatic triglyceride content in nonalcoholic fatty liver disease
inferredcites →https://doi.org/10.1002/hep.31806openalex-extracted
Glycemic Control Predicts Severity of Hepatocyte Ballooning and Hepatic Fibrosis in Nonalcoholic Fatty Liver Disease
inferredcites →https://doi.org/10.1002/hep.32499openalex-extracted
Are there outcome differences between NAFLD and metabolic‐associated fatty liver disease?
inferredcites →https://doi.org/10.1002/oby.23263openalex-extracted
Type 2 diabetes mellitus increases the risk of hepatic fibrosis in individuals with obesity and nonalcoholic fatty liver disease
inferredcites →https://doi.org/10.1016/j.cld.2023.01.002openalex-extracted
Metabolic Syndrome and Its Association with Nonalcoholic Steatohepatitis
inferredcites →https://doi.org/10.1016/j.clinthera.2015.05.511openalex-extracted
Empagliflozin as Add-on Therapy to Pioglitazone With or Without Metformin in Patients With Type 2 Diabetes Mellitus
inferredcites →https://doi.org/10.1016/j.eprac.2022.03.010openalex-extracted
American Association of Clinical Endocrinology Clinical Practice Guideline for the Diagnosis and Management of Nonalcoholic Fatty Liver Disease in Primary Care and Endocrinology Clinical Settings
inferredcites →https://doi.org/10.1016/j.jhep.2020.04.025openalex-extracted
Differential effects of selective- and pan-PPAR agonists on experimental steatohepatitis and hepatic macrophages☆
inferredcites →https://doi.org/10.1016/s2213-8587(17)30092-xopenalex-extracted
Efficacy and safety of once-weekly semaglutide versus once-daily sitagliptin as an add-on to metformin, thiazolidinediones, or both, in patients with type 2 diabetes (SUSTAIN 2): a 56-week, double-blind, phase 3a, randomised trial
inferredcites →https://doi.org/10.1021/ac990724xopenalex-extracted
Quantitation of Monosaccharide Isotopic Enrichment in Physiologic Fluids by Electron Ionization or Negative Chemical Ionization GC/MS Using Di-O-isopropylidene Derivatives
inferredcites →https://doi.org/10.1038/s41467-024-47919-9openalex-extracted
The pan-PPAR agonist lanifibranor improves cardiometabolic health in patients with metabolic dysfunction-associated steatohepatitis
inferredcites →https://doi.org/10.1053/j.gastro.2012.02.003openalex-extracted
Role of Obesity and Lipotoxicity in the Development of Nonalcoholic Steatohepatitis: Pathophysiology and Clinical Implications
inferredcites →https://doi.org/10.1053/j.gastro.2013.11.049openalex-extracted
Increased De Novo Lipogenesis Is a Distinct Characteristic of Individuals With Nonalcoholic Fatty Liver Disease
inferredcites →https://doi.org/10.1056/nejmoa2036205openalex-extracted
A Randomized, Controlled Trial of the Pan-PPAR Agonist Lanifibranor in NASH
inferredcites →https://doi.org/10.1093/eurheartj/ehac605openalex-extracted
High-density lipoprotein revisited: biological functions and clinical relevance
inferredcites →https://doi.org/10.1097/hep.0000000000000263openalex-extracted
Diabetes and cirrhosis: Current concepts on diagnosis and management
inferredcites →https://doi.org/10.1097/hep.0000000000000323openalex-extracted
AASLD Practice Guidance on the clinical assessment and management of nonalcoholic fatty liver disease
inferredcites →https://doi.org/10.1111/dom.13584openalex-extracted
Effect of canagliflozin treatment on hepatic triglyceride content and glucose metabolism in patients with type 2 diabetes
inferredcites →https://doi.org/10.1111/dom.14484openalex-extracted
Non‐alcoholic fatty liver disease‐related risk of cardiovascular disease and other cardiac complications
inferredcites →https://doi.org/10.1111/dom.14650openalex-extracted
Combination therapy with pioglitazone/exenatide/metformin reduces the prevalence of hepatic fibrosis and steatosis: The efficacy and durability of initial combination therapy for type 2 diabetes ( EDICT )
inferredcites →https://doi.org/10.1111/liv.15005openalex-extracted
PPAR‐γ‐induced changes in visceral fat and adiponectin levels are associated with improvement of steatohepatitis in patients with NASH
inferredcites →https://doi.org/10.1136/bmjdrc-2021-002517openalex-extracted
Real-world weight change, adherence, and discontinuation among patients with type 2 diabetes initiating glucagon-like peptide-1 receptor agonists in the UK
inferredcites →https://doi.org/10.1210/clinem/dgab578openalex-extracted
The Emerging Role of Glucagon-like Peptide-1 Receptor Agonists for the Management of NAFLD
inferredcites →https://doi.org/10.1210/jc.2015-1587openalex-extracted
Hepatic De Novo Lipogenesis in Obese Youth Is Modulated by a Common Variant in the GCKR Gene
inferredcites →https://doi.org/10.1210/jc.2015-1966openalex-extracted
High Prevalence of Nonalcoholic Fatty Liver Disease in Patients With Type 2 Diabetes Mellitus and Normal Plasma Aminotransferase Levels
inferredcites →https://doi.org/10.1371/journal.pone.0214921openalex-extracted
Repeatability and reproducibility of multiparametric magnetic resonance imaging of the liver
inferredcites →https://doi.org/10.2337/dc15-1876openalex-extracted
Metabolic Impact of Nonalcoholic Steatohepatitis in Obese Patients With Type 2 Diabetes
inferredcites →https://doi.org/10.2337/dc20-1997openalex-extracted
Advanced Liver Fibrosis Is Common in Patients With Type 2 Diabetes Followed in the Outpatient Setting: The Need for Systematic Screening
inferredcites →https://doi.org/10.2337/dc22-2048openalex-extracted
High Prevalence of NASH and Advanced Fibrosis in Type 2 Diabetes: A Prospective Study of 330 Outpatients Undergoing Liver Biopsies for Elevated ALT, Using a Low Threshold
inferredcites →https://doi.org/10.2337/dc25-s004openalex-extracted
4. Comprehensive Medical Evaluation and Assessment of Comorbidities: Standards of Care in Diabetes—2025
inferredcites →https://doi.org/10.2337/dsi23-0010openalex-extracted
Understanding the Burden of Nonalcoholic Fatty Liver Disease: Time for Action
inferredcites →https://doi.org/10.2337/dsi23-0012openalex-extracted
Pharmacological Approaches to Nonalcoholic Fatty Liver Disease: Current and Future Therapies
inferredcites →https://doi.org/10.2337/dsi23-0013openalex-extracted
Role of Insulin Resistance in the Development of Nonalcoholic Fatty Liver Disease in People With Type 2 Diabetes: From Bench to Patient Care
inferredcites →https://doi.org/10.7326/m15-1774openalex-extracted
Long-Term Pioglitazone Treatment for Patients With Nonalcoholic Steatohepatitis and Prediabetes or Type 2 Diabetes Mellitus
Editorial review for independent work. ICSAC — the Institute for Complexity
Science and Advanced Computing — runs a structured editorial panel for researchers
publishing outside journals, and publishes on CiteStamp rails. Submission is free
and goes through ORCID: icsacinstitute.org/submit.